共 154 条
[1]
Bayes-Genis A(2016)A test in context: Neprilysin: function, inhibition, and biomarker J Am Coll Cardiol 68 639-653
[2]
Barallat J(2015)Neprilysin: biotarget and biomarker in heart failure JACC Hear Fail 3 645-646
[3]
Richards AM(2015)Neprilysin in heart failure: from oblivion to center stage JACC Hear Fail. 3 637-640
[4]
Seronde MF(1986)Effect of human atrial natriuretic peptide on blood pressure after sodium depletion in essential hypertension Br Med J (Clin Res Ed) 293 351-353
[5]
Mebazaa A(1986)Inhibition of vasopressin action by atrial natriuretic factor Science. 231 1572-1573
[6]
Bayés-Genís A(2020)Circulating Neprilysin in patients with heart failure and preserved ejection fraction JACC Hear Fail. 8 70-80
[7]
Janssen WM(2019)Angiotensin-neprilysin inhibition in acute decompensated heart failure N Engl J Med 380 539-548
[8]
de Jong PE(2014)Angiotensin-neprilysin inhibition versus enalapril in heart failure N Engl J Med 371 993-1004
[9]
van der Hem GK(2019)Efficacy and safety of combined neprilysin and RAS inhibition in heart failure: a meta-analysis of randomized controlled trials Int J Cardiol 293 159-164
[10]
de Zeeuw D(2015)Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients J Am Coll Cardiol 65 657-665